Table 2.
Complete remission analysis.
| Variable | N (%) | CR–CRi (%) | p-value (univariate) | Hazard ratio (95% CI)* | p-value (multiv.) |
|---|---|---|---|---|---|
| Overall | 71 (100%) | 50 (70.4%) | – | – | – |
| Age | |||||
| <70 years | 51 (71.8) | 37 (72.5) | 0.531 | 0.901 (0.639–1.271) | – |
| >70 years | 20 (28.2) | 13 (65.0) | |||
| Sex | |||||
| Male | 39 (54.9) | 29 (74.4) | 0.446 | 0.821 (0.495–1.363) | – |
| Female | 32 (45.1) | 21 (65.6) | |||
| WBC | |||||
| <30 × 109/L | 60 (84.5) | 42 (70.0) | 1.000 | 1.020 (0.825–1.262) | – |
| >30 × 109/L | 11 (15.5) | 8 (72.7) | |||
| Marrow blasts | |||||
| <30% | 22 (31.0) | 19 (86.4) | 0.055 | 0.376 (0.124–1.136) | 0.062 |
| >30% | 49 (69.0) | 31 (63.3) | |||
| Previous HMA | |||||
| No | 54 (76.1) | 40 (74.1) | 0.361 | 0.833 (0.598–1.162) | – |
| Yes | 17 (23.9) | 10 (58.8) | |||
| NPM1 | |||||
| Wild type | 63 (92.6) | 42 (66.7) | 0.176 | 1.194 (1.012–1.235) | 0.150 |
| Mutated | 5 (7.4) | 5 (100) | |||
| FLT3-ITD | |||||
| Negative | 64 (92.8) | 45 (70.3) | 1.000 | 0.965 (0.825–1.119) | – |
| Positive | 5 (7.2) | 3 (60.0) | |||
| TP53 | |||||
| Wild type | 24 (64.9) | 18 (75.0) | 1.000 | 1.037 (0.605–1.776) | – |
| Mutated | 13 (35.1) | 10 (76.9) | |||
| Karyotype | |||||
| Fav./Int. | 39 (54.9) | 31 (79.5) | 0.074 | 0.614 (0.342–1.105) | 0.057 |
| Poor | 32 (45.1) | 19 (59.4) | |||
| Therapy related | |||||
| No | 49 (69.0) | 37 (75.5) | 0.260 | 0.752 (0.515–1.158) | – |
| Yes | 22 (31.0) | 13 (59.1) | |||
| ELN 2017 | |||||
| Low/Int. | 32 (45.1) | 25 (78.1) | 0.296 | 0.667 (0.343–1.297) | – |
| High | 39 (54.9) | 25 (64.1) | |||
*Hazard ratio calculation refers to the first row of each variable.